Molecular identification of adenoviruses associated with respiratory infection in Egypt from 2003 to 2010

  • Pola N Demian1,

    Affiliated with

    • Katherine C Horton1,

      Affiliated with

      • Adriana Kajon2,

        Affiliated with

        • Rania Siam3,

          Affiliated with

          • Amel Mohamed Nageib Hasanin4,

            Affiliated with

            • Amany Elgohary Sheta4,

              Affiliated with

              • Claire Cornelius1, 6 and

                Affiliated with

                • Anne M Gaynor1, 5Email author

                  Affiliated with

                  BMC Infectious Diseases201414:50

                  DOI: 10.1186/1471-2334-14-50

                  Received: 3 February 2013

                  Accepted: 14 January 2014

                  Published: 30 January 2014

                  Abstract

                  Background

                  Human adenoviruses of species B, C, and E (HAdV-B, –C, -E) are frequent causative agents of acute respiratory infections worldwide. As part of a surveillance program aimed at identifying the etiology of influenza-like illness (ILI) in Egypt, we characterized 105 adenovirus isolates from clinical samples collected between 2003 and 2010.

                  Methods

                  Identification of the isolates as HAdV was accomplished by an immunofluorescence assay (IFA) and confirmed by a set of species and type specific polymerase chain reactions (PCR).

                  Results

                  Of the 105 isolates, 42% were identified as belonging to HAdV-B, 60% as HAdV–C, and 1% as HAdV-E. We identified a total of six co-infections by PCR, of which five were HAdV-B/HAdV-C co-infections, and one was a co-infection of two HAdV-C types: HAdV-5/HAdV-6. Molecular typing by PCR enabled the identification of eight genotypes of human adenoviruses; HAdV-3 (n = 22), HAdV-7 (n = 14), HAdV-11 (n = 8), HAdV-1 (n = 22), HAdV-2 (20), HAdV-5 (n = 15), HAdV-6 (n = 3) and HAdV-4 (n = 1). The most abundant species in the characterized collection of isolates was HAdV-C, which is concordant with existing data for worldwide epidemiology of HAdV respiratory infections.

                  Conclusions

                  We identified three species, HAdV-B, -C and -E, among patients with ILI over the course of 7 years in Egypt, with at least eight diverse types circulating.

                  Keywords

                  Adenovirus Influenza-like illness Respiratory illness Egypt

                  Background

                  Human adenoviruses (HAdV) belong to the family Adenoviridae and the genus Mastadenovirus. Seven HAdV species are formally recognized by the International Committee on Taxonomy of Viruses, indicated by letters A-G and encompassing the 54 accepted HAdV types, designated by numbers 1 through 54. The clinical manifestations of HAdV infection varies with the species and type of virus, ranging from asymptomatic infection to mild respiratory (HAdV-B1, HAdV-C, HAdV-E), gastrointestinal (HAdV-F), and ocular (HAdV-B, HAdV-D, HAdV-E) disease. Life threatening pneumonia, septicemia and endocarditis are also possible in immunecompromised individuals or those with an underlying a comorbidity [15].

                  Among HAdV-associated acute respiratory disease, the majority of infections are caused by three species: HAdV-B, HAdV-C, and HAdV-E [6]. Approximately 60% of HAdV infections in children and young adults are caused by HAdV-C [711], and asymptomatic carriers of HAdV-C are frequently detected due to the ability of this species to establish persistent infections [7, 12, 13]. HAdV-B (HAdV-3, -7, -11, -14, -16, and -21) and HAdV-E (HAdV-4) are most commonly associated with outbreaks of acute febrile respiratory illness, conjunctivitis, and pneumonia in crowded populations [1417]. Co-infections with multiple types, either from the same species or different species, have been shown to occur frequently in immunocompromised patients [18, 19] and have been documented in other susceptible populations [20, 21].

                  Compared to other regions of the globe, relatively few studies have examined the contribution of HAdV to the burden of respiratory, ocular, or enteric disease in Egypt [6, 2226]. Only one study was conducted in Egypt to determine the most prevalent species and types of HAdV-associated influenza-like illness (ILI) [6]. In the current study, we used a molecular typing approach to characterize HAdV species and types associated with ILI from eight sites across Egypt from 2003–2010.

                  Methods

                  Sample collection

                  Adenovirus isolates (n = 105) examined in this study were derived from oropharyngeal (OP) swabs (n = 99) obtained from patients that presented to one of eight surveillance sites from 2003–2010 (Figure  1). All samples were obtained from pediatric and adult patients that met the World Health Organization (WHO) ILI surveillance case definition (fever >38°C and respiratory manifestations of cough, sore throat or coryza with onset of illness within the previous 3 days) and were enrolled. OP swabs were obtained along with basic demographic information. OP swabs were placed in viral transport medium (VTM) and transported to NAMRU-3 in Cairo, Egypt, where they were stored at -70°C until further processing.
                  http://static-content.springer.com/image/art%3A10.1186%2F1471-2334-14-50/MediaObjects/12879_2013_3025_Fig1_HTML.jpg
                  Figure 1

                  Map displaying locations of 8 surveillance sites through Egypt, grouped by region – Alexandria (blue), Delta Region (purple), Greater Cairo (green), and Upper Egypt (orange). The number of isolates by species and type for each region is displayed in Table  1.

                  Ethical approval

                  Ethical approval was obtained from the institutional review board (IRB) of the US Naval Medical Research Unit No. 3 (NAMRU-3), protocol DOD#NAMRU3.2004.0023 (N3 169), in compliance with all applicable federal regulations governing the protection of human subjects. Written informed consent was waived by the IRB, and samples contained no patient identifiers or links to clinical data. The protocol, including the exemption of written informed consent, received signatory approval from the Egyptian Ministry of Health and Population prior to IRB approval.

                  Virus isolation

                  Clinical specimens were treated with 10 μl of each of the following antibiotics: penicillin (100,000U/ml)/streptomycin (100,000 μg/ml), gentamicin (50 mg/ml)) and amphotericin B (2.50 μg/ml) as an anti-fungal agent, for ten minutes. 100 μl of each sample was inoculated onto three cell lines: MDCK (ATCC# CCL-34), NCI-H292 (ATCC# CRL-1848) and LLC-MK2 (ATCC# CCL-7.1) to maximize recovery of respiratory viral pathogens. Cell cultures were examined for cytopathic effect (CPE) for 12–14 days post-inoculation. One hundred and five HAdV isolates were recovered. HAdV identification was determined by indirect immunoflourescence antibody (IFA) test (Respiratory Viral Screen IFA Kit, LIGHT DIAGNOSTICS™, Millipore, MA, USA). After confirmation, infected tissue culture fluid (ITCF) was collected and stored at -70°C until further processing.

                  DNA extraction

                  DNA was extracted from 200 μl of ITCF using MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche). Extracted DNA was stored at -20°C for further analysis.

                  Control strains for adenovirus

                  The prototype strains of HAdV were obtained from American Type Culture Collection (ATCC): HAdV-1 (VR-1), -2 (VR-846), -3 (VR-3), -4 (VR-1572), -5 (VR-5), -6 (VR-6), -7 (VR-7), -11 (VR-12), -14 (VR-15), and -21 (VR-256) to be used as controls.

                  Molecular identification of adenovirus species and genotype

                  Primers used for adenovirus identification and species determination were obtained from the literature. For PCR confirmation of HAdV IFA positives, we used the universal primers designed by Xu et al. [27] and followed their protocol and cycling conditions with the exception of using a 25 μl reaction instead of the 50 μl used in the paper. Determination of viral species was accomplished by a minor modification of the BCE Multiplex [28] by utilizing the HadV-B reaction as a monoplex and maintaining a duplex reaction for HAdV-C and HAdV-E. This multiplex is able to discriminate between HAdV4a-like and HAdV-4p-like based on a 30 bp insertion/deletion mutation in the E1A gene, as described previously [11]. For further PCR-based typing of HAdV-B positive samples, multiplex PCR for HAdV-3, 7 and 21 [29] was performed, and any negative samples were then tested with specific assays for HAdV-11, 14, 16, and 35, as previously described [6]. Typing of the HAdV-C species was performed by a multiplex PCR targeting the fiber gene [30]. All PCR reactions were performed as described in their respective publications. All products were run on a 2% agarose gel at 100 V with ethidium bromide and were visualized and recorded by photography on a UV light box.

                  Data analysis

                  Data were analyzed using SAS software, version 9, of the SAS System for Windows (SAS Institute Inc). Chi-square goodness of fit test was used to assess significance of bivariate associations. When expected values did not meet the frequency assumptions required for this test, Fisher’s exact test was used. Associations were considered significant by a p-value less than 0.05.

                  Results

                  In this study, we sought to characterize adenovirus isolates with the aim of identifying the most prevalent species and types circulating in Egypt in recent years. OP swabs from patients with ILI were collected during the period 2003–2010. The samples were tested for the presence of a viral etiology by inoculation onto cell monolayer and the observed for CPE. Samples showing CPE were then screened for HAdV by an immunofluorescence assay and confirmed with our PCR testing algorithm. A total of 105 HAdV isolates were identified among the 99 HAdV-positive samples; 44 (42%) were HAdV-B, 60 (57%) were HAdV-C, and 1 (1%) was HAdV-E (Table  1, Figure  2). Co-infections were detected in 6 (6%) of the 99 specimens, 5 (5%) with HAdV-B and HAdV-C and 1 (1%) with two different types of HAdV-C. Molecular typing of HAdV-B species (Figure  2) identified the following types: HAdV-3 (n = 22), HAdV-7 (n = 14), and HAdV-11 (n = 8) (p = 0.03). Among the HAdV-C isolates, we identified significantly more HAdV-1 (n = 22) and HAdV-2 (n = 20) than HAdV-5 (n = 15) and HAdV-6 (n = 3) (p < 0.01). One sample in this group contained a coinfection of HAdV-5/HAdV-6. The five HAdV-B/HAdV-C coinfections included HAdV-3/HAdV-1 (n = 3), HAdV-3/HAdV-2 (n = 1), and HAdV-3/HAdV-5 (n = 1). The only HAdV-E isolate was typed as a HAdV-4a-like genomic variant.
                  Table 1

                  Descriptive data, by year, region, age and sex, for HAdV infections by species and genotype (n = 105)

                   

                  HAdV-B

                  HAdV-C

                  HAdV-E

                  TOTAL

                   

                  HAdV-3

                  HAdV-7

                  HAdV-11

                  Total

                  HAdV-1

                  HAdV-2

                  HAdV-5

                  HAdV-6

                  Total

                  HAdV-4

                  Total

                   
                   

                  n

                  %

                  n

                  %

                  n

                  %

                  n

                  %

                  n

                  %

                  n

                  %

                  n

                  %

                  n

                  %

                  n

                  %

                  n

                  %

                  n

                  %

                   

                  Year

                      

                    2003

                  0

                  0%

                  0

                  0%

                  0

                  0%

                  0

                  0%

                  1

                  50%

                  0

                  0%

                  0

                  0%

                  1

                  50%

                  2

                  100%

                  0

                  0%

                  0

                  0%

                  2

                    2004

                  0

                  0%

                  0

                  0%

                  0

                  0%

                  0

                  0%

                  0

                  0%

                  0

                  0%

                  0

                  0%

                  0

                  0%

                  0

                  0%

                  0

                  0%

                  0

                  0%

                  0

                    2005

                  2

                  40%

                  0

                  0%

                  2

                  40%

                  4

                  80%

                  0

                  0%

                  0

                  0%

                  1

                  20%

                  0

                  0%

                  1

                  20%

                  0

                  0%

                  0

                  0%

                  5

                    2006

                  3

                  38%

                  0

                  0%

                  0

                  0%

                  3

                  38%

                  2

                  25%

                  2

                  25%

                  1

                  13%

                  0

                  0%

                  5

                  63%

                  0

                  0%

                  0

                  0%

                  8

                    2007

                  2

                  20%

                  0

                  0%

                  1

                  10%

                  3

                  30%

                  3

                  30%

                  1

                  10%

                  3

                  30%

                  0

                  0%

                  7

                  70%

                  0

                  0%

                  0

                  0%

                  10

                    2008

                  3

                  30%

                  4

                  40%

                  1

                  10%

                  8

                  80%

                  0

                  0%

                  2

                  20%

                  0

                  0%

                  0

                  0%

                  2

                  20%

                  0

                  0%

                  0

                  0%

                  10

                    2009

                  9

                  29%

                  5

                  16%

                  1

                  3%

                  15

                  48%

                  6

                  19%

                  5

                  16%c

                  4

                  13%

                  0

                  0%

                  15

                  48%

                  1

                  3%

                  1

                  3%

                  31

                    2010

                  3

                  8%

                  5

                  13%

                  3

                  8%

                  11

                  28%

                  10

                  26%

                  10

                  26%

                  6

                  15%

                  2

                  5%

                  28

                  28

                  0

                  0%

                  0

                  0%

                  39

                  Region

                      

                    Alexandria

                  8

                  33%

                  0

                  0%

                  0

                  0%

                  8

                  33%

                  7

                  29%

                  5

                  21%

                  2

                  8%

                  1

                  4%

                  15

                  63%

                  1

                  4%

                  1

                  4%

                  24

                    Delta

                  2

                  22%

                  3

                  33%

                  1

                  11%

                  6

                  67%c

                  3

                  33%

                  0

                  0%

                  0

                  0%

                  0

                  0%

                  3

                  33%

                  0

                  0%

                  0

                  0%

                  9

                    Greater Cairo

                  8

                  19%

                  8

                  19%

                  7

                  17%

                  23

                  55%

                  5

                  12%

                  6

                  14%

                  7

                  17%

                  1

                  2%

                  19

                  45%

                  0

                  0%

                  0

                  0%

                  42

                    Upper Egypt

                  4

                  13%

                  3

                  10%

                  0

                  0%

                  7

                  23%

                  7

                  23%

                  9

                  30%

                  6

                  20%

                  1

                  3%

                  23

                  77%

                  0

                  0%

                  0

                  0%

                  30

                  Age

                      

                    < 2 years

                  3

                  8%

                  5

                  14%

                  0

                  0%

                  8

                  22%

                  8

                  22%

                  8

                  22%

                  10

                  28%

                  1

                  3%

                  27

                  75%

                  1

                  3%

                  1

                  3%

                  36

                    2-17 years

                  11

                  23%

                  9

                  19%

                  7

                  15%

                  27

                  56%

                  7

                  15%

                  9

                  19%

                  3

                  6%

                  2

                  4%

                  21

                  44%

                  0

                  0%

                  0

                  0%

                  48

                    ≥ 18 years

                  7

                  37%

                  0

                  0%

                  1

                  5%

                  8

                  42%

                  6

                  32%

                  3

                  16%

                  2

                  11%

                  0

                  0%

                  11

                  58%

                  0

                  0%

                  0%

                  0%

                  19

                    Unknown

                  1

                  50%

                  0

                  0%

                  0

                  0%

                  1

                  50%

                  1

                  50%

                  0

                  0%

                  0

                  0%

                  0

                  0%

                  1

                  50%

                  0

                  0%

                  0

                  0%

                  2

                  Sex

                      

                    Male

                  7

                  17%

                  8

                  19%

                  4

                  10%

                  19

                  45%

                  7

                  17%

                  9

                  21%

                  5

                  12%

                  2

                  5%

                  23

                  55%

                  0

                  0%

                  0

                  0%

                  42

                    Female

                  14

                  23%

                  6

                  10%

                  4

                  7%

                  24

                  39%

                  14

                  23%

                  11

                  18%

                  10

                  16%

                  1

                  2%

                  36

                  59%

                  1

                  2%

                  1

                  2%

                  61

                    Unknown

                  1

                  50%

                  0

                  0%

                  0

                  0%

                  1

                  50%

                  1

                  50%

                  0

                  0%

                  0

                  0%

                  0

                  0%

                  1

                  50%

                  0

                  0%

                  0

                  0%

                  2

                  TOTAL

                  22

                  21%

                  14

                  13%

                  8

                  8%

                  44

                  42%

                  22

                  21%

                  20

                  19%

                  15

                  14%

                  3

                  3%

                  60

                  57%

                  1

                  1%

                  1

                  1%

                  105

                  http://static-content.springer.com/image/art%3A10.1186%2F1471-2334-14-50/MediaObjects/12879_2013_3025_Fig2_HTML.jpg
                  Figure 2

                  Distribution of adenovirus positive isolates (n = 105), by species – HAdV-B (red), HAdV-C (blue), HAdV-E (purple) – and type.

                  Distribution of HAdV species among age groups

                  The age range of patients from whom HAdV isolates were obtained was 2 months to 56 years. Thirty-six of the 105 HAdV isolates were obtained from children under two years of age (Table  1, Figure  3). Of those, HAdV-C (n = 27) was more common than HAdV-B (n = 8) or HAdV-E (n = 1) (p < 0.01). Three (9%) samples had HAdV-B/HAdV-C coinfections and 1 (3%) had a HAdV-C coinfection. Forty-eight isolates were recovered from children ages 2 through 17 years. Of these, there was no statistical difference in serotypes (p = 0.12) or coinfections identified. In the third age group, 18 years of age and older, 19 isolates were recovered, including one HAdV-B/HAdV-C coinfection, again with no significant differences (p = 0.81). Age is unknown for one of the HAdV-B/HAdV-C coinfections. Across the entire patient population, HAdV-B was significantly more common among ages 2 through 17 (p < 0.01) and HAdV-C was significantly more common in ages less than 2 (p < 0.01). Coinfections were significantly more likely in patients under age 2 than in older patients (p = 0.04).
                  http://static-content.springer.com/image/art%3A10.1186%2F1471-2334-14-50/MediaObjects/12879_2013_3025_Fig3_HTML.jpg
                  Figure 3

                  Distribution of adenovirus positive isolates by age-group and species (n = 105) – HAdV-B (red), HAdV-C (blue), HAdV-E (purple).

                  Geographic distribution of HAdV species

                  Clinical specimens were obtained at eight surveillance sites distributed throughout 4 major regions in Egypt (Table  1, Figure  1). In Alexandria, HAdV-C was relatively more prevalent than HAdV-B (p < 0.01). The only HAdV-E strain was also isolated from this location. Samples collected in Upper Egypt were significantly more likely to be HAdV-C (n = 23) than HAdV-B (n = 7) (p < 0.01). There were no statistically significant differences in species proportions in the Delta region (p = 0.32) or in Greater Cairo (p = 0.54).

                  Distribution of species by year of isolation and season

                  Significantly more isolates, 59%, were recovered from samples collected from March-June, which represents the spring and beginning of summer when average temperatures increase from 15°C in February to between 17°C and 27°C, than in the rest of the year (p < 0.01) (Table  2). Only 28% of isolates were recovered from samples during the typical influenza virus season (September-February). From the beginning of surveillance, none of the identified types circulated continuously during the eight years of sampling. HAdV-3 (HAdV-B) and HAdV-5 (HAdV-C) were detected every year after first being identified in 2005 (Table  2). HAdV-2 appeared in 2006, and HAdV-7 in 2008, and both circulated through 2010. The other types were identified sporadically throughout the surveillance period. The only HAdV-E isolate was recovered in April 2009.
                  Table 2

                  Distribution of HAdV infections by month and year (n = 105)

                   

                  Jan

                  Feb

                  Mar

                  Apr

                  May

                  Jun

                  Jul

                  Aug

                  Sep

                  Oct

                  Nov

                  Dec

                  2003

                  0

                  0

                  0

                  2

                  0

                  0

                  0

                  0

                  0

                  0

                  0

                  0

                  2004

                  0

                  0

                  0

                  0

                  0

                  0

                  0

                  0

                  0

                  0

                  0

                  0

                  2005

                  0

                  0

                  0

                  0

                  0

                  1

                  0

                  2

                  0

                  2

                  0

                  0

                  2006

                  0

                  0

                  1

                  0

                  0

                  0

                  1

                  0

                  1

                  0

                  3

                  2

                  2007

                  1

                  2

                  1

                  0

                  0

                  6

                  0

                  0

                  0

                  0

                  0

                  0

                  2008

                  0

                  0

                  0

                  0

                  2

                  0

                  1

                  3

                  0

                  2

                  1

                  1

                  2009

                  1

                  2

                  8

                  5

                  3

                  4

                  1

                  0

                  0

                  3

                  2

                  2

                  2010

                  0

                  4

                  5

                  7

                  9

                  8

                  4

                  2

                  0

                  0

                  0

                  0

                  TOTAL

                  2

                  8

                  15

                  14

                  14

                  19

                  7

                  7

                  1

                  7

                  6

                  5

                  Discussion

                  In this retrospective study, we characterized HAdV isolates derived from an ILI surveillance program conducted as collaboration between the Egyptian Ministry of Health and Population and NAMRU-3 between 2003 and 2010. This study builds on knowledge gleaned from previous work conducted by Metzgar et al. that examined isolates in the NAMRU-3 collection from 1999 to 2002 [6].

                  Data from the current study indicate that HAdV continues to circulate among outpatients with ILI in Egypt and that HAdV-B and HAdV-C appear to remain the most prevalent species within this patient population. In contrast to the earlier results reported by Metzgar et al., HAdV-C was recovered in a higher prevalence than HAdV-B [6]. Though not statistically significant (p = 0.11), this relative prevalence is consistent with findings in Malaysia [7], though differs from studies in the United Kingdom [17] and Korea [31]. Unfortunately additional data from elsewhere in the region are not available for comparison. Differences in dominant HAdV species could be due to factors such as variations in geographic location, time period and sampling methodologies. Additionally, studies also indicate that HAdV-C is the most prevalent HAdV recovered from upper respiratory tract infections, in agreement with our findings from outpatients with ILI [32, 33], whereas HAdV-B1 serotypes (HAdV-3, -7) are more prominent in lower respiratory tract infections [28, 3437]. Another possible explanation is that we may have detected both active and latent infections of HAdV-C through use of OP swabs [38], since laboratory methods used do not allow us to differentiate the two [28, 32, 34, 37, 39].

                  Among the HAdV-B isolates recovered, significantly more cases of HAdV-3 and HAdV-7, the primary HAdV-B types in respiratory infections, were identified, both of which have been associated with severe outbreaks and are classified in subspecies HAdV-B1 [6]. Contrastingly, infection with HAdV-11 (subspecies HAdV-B2) appears rare, especially in respiratory infections [40]. HAdV-1 was the most common HAdV-C type identified, followed by HAdV-2 and HAdV-5. Only two HAdV-6 isolates were identified in our collection of HAdV isolates, and this type was not detected in the previous study in Egypt [6]. Comparable proportions of HAdV-1, -2 and -5 were identified by Garnett et al., though this distribution is unexpected since HAdV-1 and -2 are more generally common in respiratory infections than HAdV-5 [38]. The HAdV-E isolate was typed as HAdV-4, the sole human type in this species, which is relatively rare in civilian populations, though associated with viral conjunctivitis outbreaks in Japan [41] and Australia [42]. It is more commonly associated with high rates of febrile respiratory illness in US military recruits [6, 4345]. The single HAdV-4 isolate was identified in April, which preceded the introduction of influenza A (H1N1) pdm09 into Egypt in June 2009 [46, 47].

                  HAdV-B and HAdV-C infections were significantly associated with younger patients, which is expected given that HAdV is the second most common viral respiratory pathogen in children under 2 years of age [48]. HAdV-C was strongly associated with age less than 2, which may be related to the fact that this species is often endemic in this age group [6] and that the presence of HAdV-C in the tonsils peaks at age 4 [38]. Although HAdV-E is typically associated with adult infection [32], the only case observed in this study occurred in a child under two years of age. Adenoviral coinfections were also more frequent among patients under age 2 (p = 0.04). It should be noted that this study might have under-estimated the number of coinfections due to the testing algorithm that was utilized. The initial isolation was performed in cell lines routinely used in our laboratory for recovery of all respiratory viruses. However, given the differences in known cell surface receptors for HAdV types, we could have biased our isolation of certain species and types, and therefore also coinfections within a given sample. The PCR protocol for HAdV-B typing could have also led to under-estimation. Samples that were HAdV-B positive, but negative for the HAdV-3/7/21 multiplex were tested for the remainder of the HAdV-B types, HAdV-11, -14, -16, and -35, but samples that were positive for HAdV-3/7/21 were not tested for the additional types, and we could have missed samples that contained a coinfection of multiple types of HAdV-B.

                  HAdV occurs throughout the year, with outbreaks that are common from late winter through early summer months [5]. Although denominator data to support examination of seasonality are not available, it is notable that 58 out of the 105isolates identified in this study were isolated over a four-month period from March through June (Table  2), suggesting that the peak of circulation occurred during this time frame. This timing is also consistent with the expected circulation of HAdV-C [32], which was the most frequent species observed in this study. Larger sample sizes and broader surveillance data on ILI are required to fully delineate the seasonal distribution of HAdV.

                  Human adenovirus infections are a significant cause of a wide range of disease, including respiratory infections [28, 33, 49], and this study has established that HAdV continues to circulate in Egypt. The dominant species in circulation appears to be HAdV-C, though HAdV-B and HAdV-E have also been identified in patients with ILI. The circulation of HAdV-3, HAdV-5 and HAdV-7 is of note as these types are recognized causes of more severe acute respiratory infection [50]. Scientists and medical personnel concerned with the etiology of acute respiratory infections in Egypt should consider HAdV as a potential cause, given this evidence of infection among patients with ILI.

                  Conclusions

                  We identified three species, HAdV-B, -C and -E, among patients with ILI over the course of 7 years in Egypt, with at least eight diverse types circulating. Continued surveillance and characterization is necessary to understand the contribution of HAdV and its genotypes to acute respiratory disease in the region.

                  Abbreviations

                  ATCC: 

                  American Type Culture Collection

                  CPE: 

                  Cytopathic effect

                  DNA: 

                  Deoxyribonucleic acid

                  HAdV: 

                  Human adenovirus

                  IFA: 

                  Indirect immunofluorescence assay

                  ILI: 

                  Influenza-like illness

                  ITCF: 

                  Infected tissue culture fluid

                  LLC-MK2: 

                  Rhesus Monkey Kidney Epithelial Cells

                  MDCK: 

                  Madin Darby Canine Kidney

                  NAMRU-3: 

                  US Naval Medical Research Unit-3

                  NCI-H292: 

                  National Cancer Institute: Human mucoepidermoid pulmonary carcinoma

                  OP: 

                  Oropharyngeal

                  PCR: 

                  Polymerase chain reaction

                  VTM: 

                  Viral transport media.

                  Declarations

                  Acknowledgements

                  We thank James Pethers, Robert Coon, and Christopher A. Myers at the Naval Health Research Center (NHRC) in San Diego, CA, for the training they provided and assistance in testing the samples. We thank Iman Medhat Younis, Maha El Badry, and Mustafa Abd El-Aziz at NAMRU-3 for their assistance with virus isolation. Pola Demian was partially funded by a Laboratory Fellowship from the American University in Cairo.

                  Disclaimers

                  This study was supported by the governments of Egypt and the United States. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, the U.S. Governments or the Egyptian Ministry of Health and Population. Work was funded by work unit # 847705.82000.25GB.E0018. Authors PD, KH, CC and AG are employees of the U.S. Government. This work was prepared as part of their official duties. The work of A.E.K. was funded by the Global Emerging Infections Surveillance and Response System, a Division of the US Armed Forces Health Surveillance Center. Title 17 U.S.C. §105 provides that ‘Copyright protection under this title is not available for any work of the United States Government.’ Title 17 U.S.C. §101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person’s official duties.

                  Authors’ Affiliations

                  (1)
                  U.S. Naval Medical Research Unit No. 3
                  (2)
                  Lovelace Respiratory Research Institute
                  (3)
                  Biology Department and the YJ-Science and Technology Research Center, American University in Cairo
                  (4)
                  Ministry of Health and Population
                  (5)
                  School of Veterinary Medicine, University of California
                  (6)
                  218th Medical Detachment, (Veterinary Service Support), 47th Combat Support Hospital, 62nd Medical Brigade

                  References

                  1. Luksic I, et al.: Viral etiology of hospitalized acute lower respiratory infections in children under 5 years of age – a systematic review and meta-analysis. Croat Med J 2013,54(2):122–134.PubMed CentralPubMedView Article
                  2. Adeyemi OA, Yeldandi AV, Ison MG: Fatal adenovirus pneumonia in a person with AIDS and Burkitt lymphoma: a case report and review of the literature. AIDS Read 2008,18(4):196–198. 201–2, 206–7PubMed
                  3. Adeyi OA, et al.: Posttransplant adenoviral enteropathy in patients with small bowel transplantation. Arch Pathol Lab Med 2008,132(4):703–705.PubMed
                  4. Pham TT, Burchette JL Jr, Hale LP: Fatal disseminated adenovirus infections in immunocompromised patients. Am J Clin Pathol 2003,120(4):575–583.PubMedView Article
                  5. Hess BDJ: Non-influenza Respiratory Viruses, in Hospital Physician Infectious Diseases Board Review Manual, M. V, Editor. Wayne, PA: Turner White Communications Inc; 2012:5–16.
                  6. Metzgar D, et al.: PCR analysis of egyptian respiratory adenovirus isolates, including identification of species, serotypes, and coinfections. J Clin Microbiol 2005,43(11):5743–5752.PubMed CentralPubMedView Article
                  7. Abd-Jamil J, et al.: Molecular identification of adenovirus causing respiratory tract infection in pediatric patients at the University of Malaya Medical Center. BMC Pediatr 2010, 10:46.PubMed CentralPubMedView Article
                  8. Brandt CD, et al.: Infections in 18,000 infants and children in a controlled study of respiratory tract disease.II. Variation in adenovirus infections by year and season. Am J Epidemiol 1972,95(3):218–227.PubMed
                  9. Houng HS, et al.: Emergence of a new human adenovirus type 4 (Ad4) genotype: identification of a novel inverted terminal repeated (ITR) sequence from majority of Ad4 isolates from US military recruits. J Clin Virol 2006,35(4):381–387.PubMedView Article
                  10. Kajon AE, et al.: Outbreak of febrile respiratory illness associated with adenovirus 11a infection in a Singapore military training camp. J Clin Microbiol 2010,48(4):1438–1441.PubMed CentralPubMedView Article
                  11. Kajon AE, et al.: Molecular epidemiology of adenovirus type 4 infections in US military recruits in the postvaccination era (1997–2003). J Infect Dis 2007,196(1):67–75.PubMedView Article
                  12. Andiman WA, Miller G: Persistent infection with adenovirus types 5 and 6 in lymphoid cells from humans and woolly monkeys. J Infect Dis 1982,145(1):83–88.PubMedView Article
                  13. Chu Y, et al.: Persistent infection of human adenovirus type 5 in human monocyte cell lines. Virology 1992,188(2):793–800.PubMedView Article
                  14. Chmielewicz B, et al.: Respiratory disease caused by a species B2 adenovirus in a military camp in Turkey. J Med Virol 2005,77(2):232–237.PubMedView Article
                  15. Russell KL, et al.: Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999–2004. Vaccine 2006,24(15):2835–2842.PubMed CentralPubMedView Article
                  16. Cao B, et al.: Viral and Mycoplasma pneumoniae community-acquired pneumonia and novel clinical outcome evaluation in ambulatory adult patients in China. Eur J Clin Microbiol Infect Dis 2010,29(11):1443–1448.PubMedView Article
                  17. Cooper RJ, et al.: The epidemiology of adenovirus infections in Greater Manchester, UK 1982–96. Epidemiol Infect 2000,125(2):333–345.PubMedView Article
                  18. Kroes AC, et al.: Sequential emergence of multiple adenovirus serotypes after pediatric stem cell transplantation. J Clin Virol 2007,38(4):341–347.PubMedView Article
                  19. Kojaoghlanian T, Flomenberg P, Horwitz MS: The impact of adenovirus infection on the immunocompromised host. Rev Med Virol 2003,13(3):155–171.PubMedView Article
                  20. Vora GJ, et al.: Co-infections of adenovirus species in previously vaccinated patients. Emerg Infect Dis 2006,12(6):921–930.PubMedView Article
                  21. Lin B, et al.: Use of oligonucleotide microarrays for rapid detection and serotyping of acute respiratory disease-associated adenoviruses. J Clin Microbiol 2004,42(7):3232–3239.PubMed CentralPubMedView Article
                  22. El-Mahallawy HA, et al.: Community respiratory viruses as a cause of lower respiratory tract infections following suppressive chemotherapy in cancer patients. J Egypt Natl Canc Inst 2005,17(2):121–126.PubMed
                  23. El-Sayed Zaki M, Abd-El Fatah GA: Rapid detection of oculopathogenic adenovirus in conjunctivitis. Curr Microbiol 2008,56(2):105–109.PubMedView Article
                  24. El-Shewy TE-MB, El-Bolkeiny N: Diagnostic Cytology In Some Conjunctival Diseases. Bull Opthalmol Soc Egypt 1976, 69:27–37.
                  25. El Sayed Zaki M, Goda T: Clinico-pathological study of atypical pathogens in community-acquired pneumonia: a prospective study. J Infect Dev Ctries 2009,3(3):199–205.PubMedView Article
                  26. Kamel AH, et al.: Predominance and circulation of enteric viruses in the region of Greater Cairo, Egypt. J Clin Microbiol 2009,47(4):1037–1045.PubMed CentralPubMedView Article
                  27. Xu W, McDonough MC, Erdman DD: Species-specific identification of human adenoviruses by a multiplex PCR assay. J Clin Microbiol 2000,38(11):4114–4120.PubMed CentralPubMed
                  28. Metzgar D, et al.: Abrupt emergence of diverse species B adenoviruses at US military recruit training centers. J Infect Dis 2007,196(10):1465–1473.PubMedView Article
                  29. Xu W, Erdman DD: Type-specific identification of human adenovirus 3, 7, and 21 by a multiplex PCR assay. J Med Virol 2001,64(4):537–542.PubMedView Article
                  30. Adhikary AK, et al.: Identification of subgenus C adenoviruses by fiber-based multiplex PCR. J Clin Microbiol 2004,42(2):670–673.PubMed CentralPubMedView Article
                  31. Hong JY, Lee HJ, Piedra PA, Choi EH, Park KH, Koh YY, Kim WS: Lower respiratory tract infections due to adenovirus in hospitalized Korean children: epidemiology, clinical features, and prognosis. Clin Infect Dis 2001,15(32):1423–1429.View Article
                  32. Schmitz H, Wigand R, Heinrich W: Worldwide epidemiology of human adenovirus infections. Am J Epidemiol 1983,117(4):455–66.PubMed
                  33. Wadell G: Molecular epidemiology of human adenoviruses. Curr Top Microbiol Immunol 1984, 110:191–220.PubMed
                  34. Alharbi S, et al.: Epidemiology of severe pediatric adenovirus lower respiratory tract infections in Manitoba, Canada, 1991–2005. BMC Infect Dis 2012, 12:55.PubMed CentralPubMedView Article
                  35. Kim YJ, et al.: Genome type analysis of adenovirus types 3 and 7 isolated during successive outbreaks of lower respiratory tract infections in children. J Clin Microbiol 2003,41(10):4594–9.PubMed CentralPubMedView Article
                  36. Ou SY, et al.: Viral pathogens of acute lower respiratory tract infection in hospitalized children from East Guangdong of China. Zhongguo Dang Dai Er Ke Za Zhi 2009,11(3):203–6.PubMed
                  37. Ryan MA, et al.: Large epidemic of respiratory illness due to adenovirus types 7 and 3 in healthy young adults. Clin Infect Dis 2002,34(5):577–82.PubMedView Article
                  38. Garnett CT, et al.: Latent species C adenoviruses in human tonsil tissues. J Virol 2009,83(6):2417–28.PubMed CentralPubMedView Article
                  39. Pereira HG: Persistent infection by adenoviruses. J Clin Pathol Suppl (R Coll Pathol) 1972, 6:39–42.View Article
                  40. Fox JP, Hall CE, Cooney MK: The Seattle Virus Watch. VII. Observations of adenovirus infections. Am J Epidemiol 1977,105(4):362–86.PubMed
                  41. Saitoh-Inagawa W, et al.: Ten years’ surveillance of viral conjunctivitis in Sapporo, Japan. Graefes Arch Clin Exp Ophthalmol 1999,237(1):35–8.PubMedView Article
                  42. Schepetiuk SK, et al.: Outbreak of adenovirus type 4 conjunctivitis in South Australia. J Med Virol 1993,41(4):316–8.PubMedView Article
                  43. Crawford-Miksza LK, Nang RN, Schnurr DP: Strain variation in adenovirus serotypes 4 and 7a causing acute respiratory disease. J Clin Microbiol 1999,37(4):1107–12.PubMed CentralPubMed
                  44. Levin S, Dietrich J, Guillory J: Fatal nonbacterial pneumonia associated with Adenovirus type 4, Occurrence in an adult. JAMA 1967,201(12):975–7.PubMedView Article
                  45. Gray GC, Callahan JD, Hawksworth AW, Fisher CA, Gaydos JC: Respiratory diseases among U.S. military personnel: countering emerging threats. Emerg Infect Dis 1999,5(3):379–85.PubMedView Article
                  46. Deming MKA, Soliman A, Afifi S, Labib M, Teesdale S: Adding real-time epidemiological surveillance to virological influenza surveillance for vaccine planning: steps needed and public health value, Egypt, 2009–2010. Adding real-time epidemiological surveillance to virological influenza surveillance for vaccine planning: steps needed and public health value, Egypt 2009–2010. Atlanta, GA: International Conference on Emerging Infectious Diseases; 2010.
                  47. Kandeel A, et al.: Pandemic (H1N1) 2009 and Hajj Pilgrims who received Predeparture Vaccination, Egypt. Emerg Infect Dis 2011,17(7):1266–8.PubMedView Article
                  48. Al-Toum R, Bdour S, Ayyash H: Adenovirus Infections in Jordanian Hospitalized Pediatric Patients: Prevalence and Clinical Features. J Med J 2009,43(3):5743–52.
                  49. Russell WC: Adenoviruses: update on structure and function. J Gen Virol 2009,90(Pt 1):1–20.PubMedView Article
                  50. Biere B, Schweiger B: Human adenoviruses in respiratory infections: sequencing of the hexon hypervariable region reveals high sequence variability. J Clin Virol 2010,47(4):366–71.PubMedView Article
                  51. Pre-publication history

                    1. The pre-publication history for this paper can be accessed here: http://​www.​biomedcentral.​com/​1471-2334/​14/​50/​prepub

                  Copyright

                  © Demian et al.; licensee BioMed Central Ltd. 2014

                  This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.